New (S)-verbenone-isoxazoline-1,3,4-thiadiazole hybrids : synthesis, anticancer activity and apoptosis-inducing effect
Background: This study aimed to develop novel isoxazoline-1,3,4-thiadiazole hybrids from (S)-verbenone for potential anticancer treatment, particularly focusing on cytotoxic and apoptotic effects in hormone-sensitive MCF-7 and triple-negative MDA-MB-231 breast cancer cells. Methods & results: (S)-verbenone was used to synthesize hybrids through 1,3-dipolar cycloaddition, followed by thorough characterization. The compounds were screened across cancer cell lines, showing significant anticancer effects. Compound 8b notably induced apoptosis via the caspase-3/7 pathway and cell cycle arrest, displaying noteworthy cytotoxicity against MCF-7 and MDA-MB-231 cells. Conclusion: These findings underscore the potential of (S)-verbenone isoxazoline-1,3,4-thiadiazole derivatives for breast cancer therapy due to their remarkable apoptotic activity. This study highlights a promising avenue for advancing breast cancer treatment using these derivatives, founded on (S)-verbenone, showcasing their distinct potential for inducing apoptosis.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:15 |
|---|---|
| Enthalten in: |
Future medicinal chemistry - 15(2023), 17 vom: 29. Sept., Seite 1603-1619 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Fawzi, Mourad [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 23.10.2023 Date Revised 24.10.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.4155/fmc-2023-0173 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM362687358 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM362687358 | ||
| 003 | DE-627 | ||
| 005 | 20231226091743.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.4155/fmc-2023-0173 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1208.xml |
| 035 | |a (DE-627)NLM362687358 | ||
| 035 | |a (NLM)37772541 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Fawzi, Mourad |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a New (S)-verbenone-isoxazoline-1,3,4-thiadiazole hybrids |b synthesis, anticancer activity and apoptosis-inducing effect |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 23.10.2023 | ||
| 500 | |a Date Revised 24.10.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Background: This study aimed to develop novel isoxazoline-1,3,4-thiadiazole hybrids from (S)-verbenone for potential anticancer treatment, particularly focusing on cytotoxic and apoptotic effects in hormone-sensitive MCF-7 and triple-negative MDA-MB-231 breast cancer cells. Methods & results: (S)-verbenone was used to synthesize hybrids through 1,3-dipolar cycloaddition, followed by thorough characterization. The compounds were screened across cancer cell lines, showing significant anticancer effects. Compound 8b notably induced apoptosis via the caspase-3/7 pathway and cell cycle arrest, displaying noteworthy cytotoxicity against MCF-7 and MDA-MB-231 cells. Conclusion: These findings underscore the potential of (S)-verbenone isoxazoline-1,3,4-thiadiazole derivatives for breast cancer therapy due to their remarkable apoptotic activity. This study highlights a promising avenue for advancing breast cancer treatment using these derivatives, founded on (S)-verbenone, showcasing their distinct potential for inducing apoptosis | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a (S)-verbenone | |
| 650 | 4 | |a 1,3,4-thiadiazole | |
| 650 | 4 | |a apoptosis | |
| 650 | 4 | |a breast cancer | |
| 650 | 4 | |a caspase 3/7 | |
| 650 | 4 | |a hormone sensitive | |
| 650 | 4 | |a hybridization | |
| 650 | 4 | |a triple negative | |
| 650 | 7 | |a 1,3,4-thiadiazole |2 NLM | |
| 650 | 7 | |a 14IAC3GH7G |2 NLM | |
| 650 | 7 | |a verbenone |2 NLM | |
| 650 | 7 | |a 99S17893UW |2 NLM | |
| 650 | 7 | |a Antineoplastic Agents |2 NLM | |
| 700 | 1 | |a Bimoussa, Abdoullah |e verfasserin |4 aut | |
| 700 | 1 | |a Laamari, Yassine |e verfasserin |4 aut | |
| 700 | 1 | |a Oussidi, Abdellah N'ait |e verfasserin |4 aut | |
| 700 | 1 | |a Oubella, Ali |e verfasserin |4 aut | |
| 700 | 1 | |a Ketatni, El Mostafa |e verfasserin |4 aut | |
| 700 | 1 | |a Saadi, Mohamed |e verfasserin |4 aut | |
| 700 | 1 | |a Ammari, Lahcen El |e verfasserin |4 aut | |
| 700 | 1 | |a Morjani, Hamid |e verfasserin |4 aut | |
| 700 | 1 | |a Ait Itto, Moulay Youssef |e verfasserin |4 aut | |
| 700 | 1 | |a Auhmani, Aziz |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Future medicinal chemistry |d 2009 |g 15(2023), 17 vom: 29. Sept., Seite 1603-1619 |w (DE-627)NLM194822109 |x 1756-8927 |7 nnns |
| 773 | 1 | 8 | |g volume:15 |g year:2023 |g number:17 |g day:29 |g month:09 |g pages:1603-1619 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.4155/fmc-2023-0173 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 15 |j 2023 |e 17 |b 29 |c 09 |h 1603-1619 | ||